



Alpha-synuclein deposition patterns in Alzheimer's disease: association with cortical amyloid beta and variable tau load

Antonia Neubauer^{1,2,3} · Doris Weissenbrunner^{1,2} · Susanna Pekrun^{1,2} · Sigrun Roeber^{1,2} · Viktoria Ruf^{1,2} · Paul Feyen^{1,2} · Felix L. Strübing^{1,2} · Jochen Herms^{1,2,3}

Received: 1 July 2025 / Revised: 13 October 2025 / Accepted: 19 October 2025
© The Author(s) 2025

Abstract

Alpha-synuclein (α -syn) deposits are common in around half of the Alzheimer's disease (AD) cases. While direct and indirect protein interactions are suggested, the relationships between different protein aggregates remain poorly understood. Here, we aimed to characterize α -syn, amyloid beta (A β), and tau load distributions of AD patients. Protein deposits were automatically quantified with random forest pixel classifiers in immunohistochemical stains of up to 28 brain regions in 72 brains with advanced AD neuropathological change. α -syn-negative cases were distinguished from amygdala predominant, brainstem predominant, and cortical α -syn-positive cases. Relationships with age, sex, and ApoE genotype were examined. α -syn co-pathology was detected in 60% of AD cases, more frequently, although not significantly, in women. Half of these positive cases presented α -syn deposits in the cortex, around one-third predominantly in the amygdala, and the remaining cases primarily in the brainstem. A high α -syn load in the amygdala was associated with an increased cortical A β load. The cortical tau load was increased in the amygdala-predominant α -syn group, but decreased in the brainstem-predominant and cortical α -syn cases in comparison with α -syn-negative cases. ApoE4 was associated with higher hippocampal α -syn and cortical A β deposition. Younger age at death was associated with a focally higher A β and tau load. AD cases with cortical α -syn deposition tended to have a younger age at death. Here, we show that next to age, sex, and ApoE genotype, the α -syn distribution in AD is related to different A β and tau loads. This may have therapeutic relevance for identifying patients who respond to A β immunotherapy related to tau burden and underpin the need to define α -syn pathology and distribution in early disease stages.

Keywords Alzheimer's disease · Lewy body disease · Mixed pathology · Alpha-synuclein · Immunohistochemistry · Quantitative neuropathology

Abbreviations

α -syn	Alpha-synuclein
α Syn-	Alpha-synuclein deposit negative
α Syn +	Alpha-synuclein deposit positive
α Syn + A	Amygdala-predominant alpha-synuclein deposition
α Syn + B	Brainstem-predominant alpha-synuclein deposition

α Syn + C	Cortical alpha-synuclein deposition
A β	Amyloid beta
AD	Alzheimer's disease
DLB	Dementia with Lewy bodies
FDR	False discovery rate
IQR	Interquartile range
PD	Parkinson's disease

✉ Antonia Neubauer
Antonia.Neubauer@med.uni-muenchen.de

- ¹ Center for Neuropathology and Prion Research, Ludwig Maximilians University of Munich, Munich, Germany
- ² German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- ³ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

Introduction

Around 57 million people worldwide are affected by dementia, with Alzheimer's disease (AD) as the most prevalent neurodegenerative disease [41, 42] and dementia with Lewy bodies (DLB) in the second place [82]. Age and an ApoE4 allele are among the most important risk factors for AD and DLB [12, 13, 24, 44]. Although these

neurodegenerative diseases are often described with distinct clinical symptoms and varying neuropathological phenotypes, mixed disease forms are common [39, 63, 77].

The neuropathological hallmarks of AD are amyloid β ($A\beta$) plaques, neurofibrillary tangles and neuropil threads [42]. $A\beta$ is a fragment of the amyloid precursor protein. According to Thal phases (1–5), $A\beta$ plaques first appear in association cortices and in later stages in the subcortical, brainstem, and cerebellum regions [70]. Tau is a microtubule-associated protein that, in its hyperphosphorylated form, is capable of forming aggregates. These tau deposits are initially observed in the transentorhinal region (stage I) and progressively appear in limbic and isocortical regions (stage VI) as classified by Braak and Braak [15, 78]. The expansion of tau pathology correlates with cognitive decline [17].

DLB is characterized by alpha-synuclein (α -syn) aggregates in the form of intraneuronal Lewy bodies and Lewy neurites [52]. Physiologically, α -syn is a soluble protein at the presynaptic nerve terminals, participating in vesicular trafficking [19, 74]. Lewy pathology can be classified according to Braak staging, which describes its distribution from the brainstem (stage 1) to the temporal mesocortex and ultimately to the neocortex (stage 6) [16], or consensus criteria by McKeith and colleagues [51]. Five main Lewy body distribution patterns were observed in brain autopsies: olfactory only, amygdala predominant, brainstem predominant, limbic, and neocortical [5, 51].

Around 50% of AD patients present with α -syn co-pathology in addition to $A\beta$ and tau deposits [4, 30, 63, 76]. Alpha-synuclein co-pathology is associated with an accelerated cognitive decline [11, 58, 67]. In AD cases, the α -syn deposits are often described in the amygdala and to a lesser extent in other brain regions such as the brainstem, hippocampus, and neocortex [4, 33, 35, 43, 65, 71, 76]. Recently, increasing attention has been paid to the heterogeneity of α -syn distribution in AD [71]. An amygdala-predominant and a caudo-rostral pattern were distinguished in AD cohorts and suggest an adverse association between amygdala-predominant α -syn co-pathology and AD pathology [14, 30, 49, 62]; however, detailed quantitative analyses of $A\beta$ and tau are lacking.

Different associations have been described between α -syn, $A\beta$, and tau [66]. Histology and PET imaging studies propose positive correlations between α -syn co-pathology and $A\beta$ and tau deposits in AD [28, 64]. On a molecular level, there is evidence for α -syn inducing hyperphosphorylation and fibrillization of tau [32, 55]. Mouse experiments support the hypothesis of α -syn modulating tau spread [9]. Furthermore, human studies have revealed higher $A\beta$ load in α -syn-positive AD cases [72]. $A\beta$ might lead to α -syn phosphorylation and decreased degradation of α -syn and tau [47, 73]. The extent of

interactions occurring in humans has not been fully elucidated yet.

In this study, we combine the analysis of AD with and without α -syn co-pathology with the evaluation of heterogeneity in α -syn deposit distribution for improved patient stratification. According to the observed relationships between α -syn, tau, and $A\beta$ described in the literature, we hypothesized that 1) α -syn co-pathology is associated with a higher tau and $A\beta$ load and 2) different α -syn distribution patterns are associated with divergent tau and $A\beta$ loads. We applied automated immunohistochemical image analysis of α -syn, tau, and $A\beta$ in extensively annotated brain regions in a large cohort of neuropathologically confirmed AD cases. We identified α -syn-negative AD cases, amygdala-predominant, brainstem-predominant, and neocortical α -syn distribution patterns, and compared tau and $A\beta$ load between these groups. Finally, the effects of age, sex, and ApoE genotype were examined.

Materials and methods

Human cohort and neuropathological assessment

All brain samples were acquired from the Neurobiobank Munich, including sporadic and genetic cases. The Neurobiobank is based on voluntary donation. Informed consent to use the brains was given by all brain donors when alive or by closest dependents following the patient's presumed will. Brains were collected respecting the guidelines of the local ethics committee and the Code of Conduct of BrainNet Europe [37]. The use of the material for this project was approved by the Neurobiobank Munich committee. The study was conducted under the principles of the Declaration of Helsinki and in accordance with the local ethics committee. Neuropathological diagnostics were performed by at least two board-certified neuropathologists. The inclusion criteria for this study were 1) a registration of the case in the digital data form with availability of digitized slices with 2) the neuropathological diagnosis of Alzheimer's disease (AD) and 3) a Braak and Braak stage IV, V, or VI. Furthermore, inclusion criteria also include 4) available data about screening for alpha-synucleinopathy, which is standard in current protocols, and 5) availability of brown diaminobenzidine (DAB) stains in contrast to red alkaline phosphatase (AP) stains, which were used much earlier. These inclusion criteria were applied regardless of additional neuropathological diagnoses or the initial clinical assessment. 72 cases were identified in the Neurobiobank fulfilling these criteria.

In particular, cases in the subgroup α Syn + C with cortically disseminated Lewy pathology also frequently received Lewy body dementia as an additional neuropathological diagnosis (21 of 22 cases) and thus are in a spectrum with

a transition to Lewy body pathology with extensive AD-related co-pathology.

For standardized deposit quantification, this study focused on reproducibly identifiable brain regions that are part of the routine diagnostics at the Neurobiobank Munich. In total, 28 gray matter regions were selected, including cortical, subcortical, cerebellar, and brainstem regions (Fig. 1, Table S1). For economic and sustainability reasons, not every brain region was stained for every case. In particular, cases without pathological α -syn in the amygdala and brainstem regions did not necessarily receive α -syn assessment of all other brain regions. To prepare diaminobenzidine stains for light microscopy, the formalin-fixed and paraffin-embedded tissue samples were manually sectioned into 5 μ m-thick slices. Further pretreatment and staining were conducted using the automatic system of Ventana BenchMark Ultra (Roche). Sections for α -syn staining were prepared with 80% formic acid for 15 min and boiling pretreatment without further protease-mediated epitope retrieval; sections for AT8 staining received the boiling pretreatment; sections for BA4 staining were passed through 80% formic acid for 15 min. All sections received treatment with the Cell Conditioning (CC1) Tris-based buffer (Roche). Primary antibodies (Table S2) were used as follows with a Ventana antibody dilution buffer (Roche, #251–018): monoclonal antibody AT8 for phosphorylated tau staining (ThermoFisher, #MN1020; dilution 1:400), monoclonal antibody, clone 4G8, for A β (BioLegend, #800,701; dilution 1:5000), and monoclonal α -syn antibody clone 42 (BDTransduction, #610,787; dilution 1:1000). The ultraView Universal DAB Detection Kit (760-500, Roche) was used for detection. A nuclear counterstain was conducted with hematoxylin and bluing reagent (Roche). As the α -syn staining labels also physiological α -synuclein, the subsequent deposit detection tool focuses only on dense positivity like Lewy bodies and Lewy neurites (see “[Deposit detection](#)” below). Stains were digitized with a Zeiss Axio Scan Z.1 scanner with a magnification of 20, resulting in a pixel size of 0.22*0.22 μ m².

The ApoE status as well as AD-related mutations were obtained through whole genome sequencing. Briefly, DNA was isolated from 1 cm³ large tissue cubes taken from fresh-frozen cerebellum using the QIAmp DNA Mini Kit (Qiagen, 51,304). Library preparation was performed with the TruSeq PCR-free genomic DNA library prep kit (Illumina, FC-121–3003) according to the manufacturer’s instructions. Libraries underwent 2 × 150 bp paired-end sequencing on an Illumina NovaSeq machine until a minimum depth of 35X was reached. Alignment and variant calling were performed using a Snakemake pipeline incorporating the GATK best practices. After FastQC and adapter trimming, alignment to the hs1/T2T genome assembly (chm13v2.0) was performed with BWA-MEM2. Variant calling, recalibration, and joint genotyping were done using GATK version 4.0.

Subsequently, the APOE genotype was defined by concatenating the APOE-defining variants (rsID/hs1 coordinates: rs429358/chr19:47,733,380; rs7412/chr19:47,733,518).

Image analysis

The region annotation was conducted manually in Qupath (version 0.5.1) [7] in α -syn stains where available and tau stains as a second choice. The regions were labeled following a protocol to reproducibly set the location and size of the annotations (Supplementary Table S1). In cases with staining artifacts or large blood vessels, the nearest appropriate region was selected in accordance with the protocol. Samples with substantial artifacts or lacking clear orientation to define the region of interest were not included in further analysis. For substantia nigra and locus coeruleus, the annotations avoid pigmented neurons to prevent false positive pixels in the subsequent analysis. The areas were selected to be as representative as possible of the extent of the deposits. Two squares were chosen for substantia nigra and locus coeruleus, respectively, to get the mean as a more robust result. Comparing the deposit covered areas of the first and second annotations with a Wilcoxon signed-rank test, there was no significant difference, suggesting that the process is relatively reproducible (Fig. S1).

Region annotations were transferred from α -syn stains to A β and tau stains with non-rigid registration by Deeperhistreg in Python (Python version 3.10.12) [79–81]. For this co-registration, the whole slide images were downsampled by a factor of 30 to reduce the computing load. All region annotations were visually inspected after transfer and upsampling and manually corrected if necessary.

Deposit detection

The annotated regions were divided into tiles of 4096*4096 pixels (900*900 μ m²) to reach a reasonable computing capacity. The preprocessing of the tiles included color deconvolution to extract the brown diaminobenzidine signal and conversion to grayscale images, implemented in Python (Python version 3.10.12). These preprocessed images were then classified pixel-wise with a random forest pixel classifier trained with ilastik (version: ilastik-1.4.0.post1-Linux) for each staining (α -syn, A β , tau), separately. The models were trained with ten images from different brains and regions with variable deposit load. The α -syn model was optimized to detect dense deposits, mainly Lewy bodies and distinct Lewy neurites, while not labeling physiological synaptic α -syn staining. A threshold of 0.7 was chosen for all random forest classifier models. The output of the random forest pixel classifiers is a pixel-wise binary segmentation of deposits. The proportion of the positively stained area relative to the total tile area is called *covered area* or




Fig. 1 Deposit quantification across brain regions. **a** Overview of analyzed brain regions colored by hypernoms in coronal slices (A' to D') in the frame of the gyral Allen Human Brain Atlas (slices A' to D': 18, 34, 55, and 83) [3, 22]. **b** α -syn stains of three brain areas with labeled brain regions for further analysis. Blocks from left to right: cingulate gyrus, insula-claustrum-putamen, and hippocampus. Length of bar = 1 mm. **c** Example images with corresponding deposit segmentation for α -syn, tau, and A β stains. α -syn: the thick arrow labels a Lewy body; the thin arrow indicates a Lewy neurite. Tau: the thick arrow labels a neurofibrillary tangle bearing neuron; the thin arrow indicates a neuritic plaque. A β : the arrow indicates a cored plaque. Length of bar = 50 μ m. **d** Schematic overview of α -syn group and subgroup definition by thresholding α -syn-covered areas of all

brain regions (max α -syn load), of the mean cortical α -syn load (of cingulate gyrus, superior and medial temporal gyrus, and insula cortex), and of the mean brainstem α -syn load. 1 middle frontal gyrus, 2 sulcus of middle frontal gyrus, 3 cingulate gyrus, 4 sulcus between cingulate and frontal gyrus, 5 insular gyrus, 6 claustrum, 7 putamen, 8 superior temporal gyrus, 9 sulcus between superior and middle temporal gyrus, 10 middle temporal gyrus, 11 amygdala, 12 entorhinal cortex, 13 parietal gyrus, 14 medial thalamus, 15 lateral thalamus, 16 substantia nigra, 17 CA4 of hippocampus, 18 CA3, 19 CA2, 20 CA1, 21 subiculum, 22 parahippocampal gyrus, 23 striate area gyrus, 24 striate area sulcus, 25 cerebellar cortex, 26 dentate nucleus, AD Alzheimer's disease, LC locus coeruleus, max maximal, OB olfactory bulb, pred. predominant

load interchangeably. In a subsequent step, the models were tested using ten independent images from different subjects and regions and were inspected individually. For additional validation, an individual random forest classifier model was created in ilastik for each testing image to gain a reference standard. The results of the previously trained models were compared to these references and evaluated in terms of how many pixels were classified correctly (prediction accuracy) and how close the values of the absolute covered area matched the covered area in the reference independently from the exact localization of the pixels (area accuracy) (Fig. S2).

Definition of α -syn groups and subgroups in AD

Alzheimer's disease patients are heterogeneous regarding their α -syn load. The simplest distinguishing criterion is α -syn deposit negative (α Syn $-$) vs. positive (α Syn $+$). Since the α -syn extent represents a smooth transition and might vary in some borderline cases, we defined a threshold of $\geq 0.3\%$ α -syn-covered area in the individually most affected brain region to label a case as α Syn $+$ (Fig. 1). As a minimum requirement, all cases assigned α Syn $-$ needed to have at least an α -syn staining of the amygdala region, as this is one of the most affected brain areas by α -syn in AD. However, as described before [5, 51], different α -syn distribution patterns exist, with a focus on brainstem-, cortical-, and amygdala-predominant forms. To identify these patterns, the threshold of $\geq 0.3\%$ α -syn-covered area was also applied to the mean of the most affected cortical regions (cingulate gyrus, superior and medial temporal gyrus, and insula cortex) and the brainstem (value of substantia nigra or locus coeruleus or mean of both if they were available). Based on these thresholds, the α Syn $+$ group was further divided into three subgroups, namely α Syn $+$ A, with an amygdala-predominant α -syn deposition, α Syn $+$ B, with a brainstem predominant α -syn load, and α Syn $+$ C, with cortical α -syn deposits.

Statistical analysis

Epidemiological data between α -syn distribution groups were compared with a Mann–Whitney U test or Kruskal–Wallis test for continuous data, and a Chi-squared test for categorical data.

α -syn, A β , and tau loads of groups and subgroups of AD patients were compared with multiple linear regression to control for age and sex. Five clusters of brain regions were defined to condense the large number of regions, namely, cortical, subcortical, hippocampal, brainstem, and amygdala–entorhinal cluster (Fig. 1), leading to the following formula for each region cluster, respectively:

Covered area $\sim$ (sub-)group name + region name + sex + age.

“Covered area” is the covered area/load of α -syn, A β , or tau. “(Sub-)group name” represents the name of the α -syn group or subgroup defined by thresholds (see “Definition of α -syn groups and subgroups in AD” and Fig. 1). Groups/subgroups were compared pairwise. As region clusters were the input data, “region name” is a fixed effect for every individual brain region. Sex and age were added as further control parameters. As control analyses, multiple linear regression was repeated without age and sex correction, or with ApoE4 carriage as an additional control parameter, alongside age, sex, and region name. Additionally, linear mixed-effects models were applied, incorporating random effects for each subject (1 | subject ID) into the above formula.

To examine the association of α -syn load with age, sex, and ApoE status, we defined age groups (<65 years at death (<65), 65 to <75 years (65–75), 75 years or older (≥ 75)) and divided the AD patients with available ApoE status into ApoE4 carriers, defined as at least one ApoE4 allele, vs. no ApoE4. Subsequently, we applied multiple linear regression within each region cluster, controlling for the specific region names. Additional analyses were conducted, controlling for age and sex. These analyses were repeated for tau and A β load in parallel.

All p -values were corrected for false discovery rate (FDR correction in R) for each analysis, respectively. Statistical tests were conducted with R (R version 4.1.2). The significance level was set to $*p < 0.05$, $**p < 0.01$, and $***p < 0.001$. Plots were created with Python (Python version 3.10.12). Color plotting on brain atlas images was conducted with Python in combination with Inkscape (Inkscape version 1.4), and the code was made publicly available on GitHub (https://github.com/cor2ni/2D_brain_plot).

Results

To analyze the association of α -syn load and distribution with A β and tau pathology in AD, we analyzed immunohistochemical stains of up to 28 brain regions per case in 72 AD patients (Table 1). Due to a recruitment bias in voluntary brain donation, the exact ratios are exemplary and cannot be directly transferred to a new population. In particular, a shift toward younger and family-related cases is to be expected, and the following characteristics help to estimate the bias for conclusions. The cohort had a mean age at death of 72.8 years (± 11.5 years standard deviation). 56% of the subjects were female. Most of the cases had a Braak and Braak stage VI and a Thal phase 5, corresponding to an advanced stage of AD. For 66 cases, information about the ApoE status was available, revealing at least one ApoE4 allele in 58% of the subjects. An AD-related mutation (APP/PSEN1/

Table 1 Demographic, clinical and neuropathological overview of α -syn groups in Alzheimer's disease

	Available n	All	α Syn−	α Syn +	Statistic, <i>p</i> -value
n (%)	72	72 (100%)	29 (40%)	43 (60%)	
Clinical diagnosis	72	AD: 42 (58%) PD: 6 (8%)	AD: 15 (52%) PD: 0 (0%)	AD: 27 (63%) PD: 6 (14%)	
AD: n (%)					
PD: n (%)					
Sex (female:male)	72	40:32	13:16	27:16	$\chi^2 = 1.6$, $p = 0.21$
Age at onset [years]	65	61.0 $\pm$ 12.2	62.5 $\pm$ 12.7	60.2 $\pm$ 11.8	$U = 429$, $p = 0.4$
Disease duration [years]	65	11.0 $\pm$ 5.9	10.4 $\pm$ 4.9	11.4 $\pm$ 6.4	$U = 543$, $p = 0.5$
Age at death [years]	71	72.8 $\pm$ 11.5	73.7 $\pm$ 10.5	72.2 $\pm$ 12.0	$U = 561$, $p = 0.6$
Braak and Braak (IV:V:VI)	72	8:14:50	1:7:21	7:7:29	$\chi^2 = 3.2$, $p = 0.21$
Thal phase (3:4:5)	69 ^a	2:7:60	1:2:25	1:5:35	$\chi^2 = 3.4$, $p = 0.5$
TDP43 (neg:pos)	49	25:24	14:7	11:17	$\chi^2 = 2.6$, $p = 0.11$
ApoE4 allele (neg:pos)	66	28:38	15:12	13:26	$\chi^2 = 2.4$, $p = 0.12$

Age at onset/death and disease duration are presented as mean $\pm$ first standard deviation; U two-sided Mann–Whitney U test; χ^2 Chi-squared test

AD Alzheimer's disease, PD Parkinson's disease, *neg* negative, *pos* positive

^aThe three missing cases have a Thal phase ≥ 3

PSEN2/TREM2) was reported in 19 out of 72 patients (26%) (Table S3).

The deposit covered area was automatically quantified by random forest pixel classifiers in 1016 regions in α -syn stains, 1292 regions in tau stains, and 1098 regions in A β stains. By thresholding, AD patients were assigned to α Syn−, comprising 41% of the cases, and α Syn +, including 59% of the cases (Figs. 1 and 2). Thereby, α -Syn positivity was comparably common in genetic and sporadic AD cases (Table S3). The α Syn + group was further divided into three α -syn distribution patterns (Figs. 1 and 2, Table 2, Table S8): α Syn + A, comprising around one-third of the α -syn-positive cases with an almost exclusive amygdala–entorhinal α -syn load; α Syn + B, including around 12% of the α -syn-positive cases and characterized by a high brainstem α -syn load without cortical spread and a low amygdala involvement; α Syn + C, comprising around half of the α -syn-positive cases and presenting with at least focal cortical α -syn deposits together with the highest amygdala–entorhinal and a relatively high brainstem α -syn load. Although not significantly different, genetic cases and cases with the youngest age at symptom onset were predominantly assigned to α Syn− and α Syn + C groups, while the α Syn + A group was more common in sporadic cases (Fig. S3, Table S3). All groups and subgroups were evaluated regarding their A β and tau load, revealing distinct loads in different brain regions.

α -syn load and distribution in AD

The α Syn− and α Syn + cases showed a comparable distribution of age at clinical onset (two-sided Mann–Whitney U test: $p = 0.4$), disease duration ($p = 0.5$), and age at death

($p = 0.6$) (Table 1 and Fig. S3). In the α Syn + group, there were comparatively more female than male subjects, while the α Syn− group had a slight male predominance, although the difference was not significant ($p = 0.21$). In total, 58% of the patients had a clinical diagnosis of Alzheimer's disease during their lifetime (Fig. S4). While α Syn− cases were mostly diagnosed with AD (52%), not further specified dementia (24%), and frontotemporal dementia (21%), α Syn + cases were commonly diagnosed with AD (63%), Parkinson's disease (14%), not further specified dementia (9%), and dementia with Lewy bodies (7%). There was no significant difference regarding the Braak and Braak staging ($p = 0.21$) or Thal phase ($p = 0.5$) between groups. There were proportionally more TDP43-positive cases in the α Syn + group; however, not significantly ($p = 0.11$). There were also more cases carrying at least one ApoE4 allele in proportion to non-carriers in the α Syn + group than in the α Syn− group, but also not significantly ($p = 0.12$). Thus, there might be a female sex, TDP43, and ApoE4 bias in the α -syn-positive group, even without reaching significance. However, it is not clear if this association is causally related or a limitation of the available cohort.

By definition, the α Syn + cases showed a higher α -syn load than α Syn− cases. Performing multiple linear regression correcting for the specific region name, age, and sex, there was a significant difference between α Syn + and α Syn− cases in cortical, subcortical, hippocampal, amygdala–entorhinal, and brainstem region clusters (Table 3), confirming the split into these two groups. The α Syn + cases showed the highest median α -syn load in the amygdala–entorhinal area, followed by the brainstem and hippocampal region, and low coverage in subcortical areas




Fig. 2 Alpha-Synuclein (α-syn) load and distribution in Alzheimer's disease cases. **a** Median α-syn-covered area of each α-syn distribution group and subgroup. **b** Comparison of the α-syn-covered area between αSyn- and αSyn+ groups. **c** Comparison of the α-syn-covered area between αSyn- and αSyn+A (amygdala predominant), αSyn+B (brainstem predominant), and αSyn+C (cortical) α-syn-

positive subgroups. Statistics in **b** and **c** were calculated with multiple linear regression across region clusters, controlling for region names, age, and sex, and false discovery rate correction. Boxplots complemented with scatter dots for female and male patients are available in the supplementary Fig. S6. LC locus coeruleus, OB olfactory bulb

(Fig. 2). The α-syn load in cortical regions was low in the median, but showed a large variability and thereby reached the highest values of covered area in single subjects. These findings suggest a region-dependent predestination for α-syn deposits in AD with a special focus on the amygdala in many cases, as well as a broad inter-patient variability.

As additional control analyses, we conducted multiple linear regression without correction for sex and age or with ApoE4 as an additional control factor. Both models showed significantly higher α-syn load in the αSyn+ group in all region clusters. Furthermore, applying linear mixed-effects models with correction for age, sex, and a random factor for

Table 2 Demographic, clinical, and neuropathological overview of α -syn distribution subgroups

	Avail. n	α Syn–	α Syn + A (amygdala pred.)	α Syn + B (brainstem pred.)	α Syn + C (cortical α -syn)	Statistic, <i>p</i> -value
n (%)	71	29 (41%)	15 (21%)	5 (7%)	22 (31%)	
Clinical diagnosis	71	AD: 15 (52%) PD: 0 (0%)	AD: 10 (67%) PD: 0 (0%)	AD: 2 (40%) PD: 2 (40%)	AD: 14 (64%) PD: 4 (18%)	
Sex (female:male)	39:32	13:16	11:4	2:3	13:9	$\chi^2=3.9$, $p=0.28$
Age at onset [years]	64	62.5 $\pm$ 12.7	64.1 $\pm$ 8.7	64.3 $\pm$ 6.9	56.5 $\pm$ 13.6	$K=2.81$, $p=0.4$
Disease duration [years]	64	10.4 $\pm$ 4.9	12.4 $\pm$ 6.0	11.2 $\pm$ 8.5	10.8 $\pm$ 6.1	$K=1.36$, $P=0.71$
Age at death	70	73.7 $\pm$ 10.5	76.5 $\pm$ 9.2	76.6 $\pm$ 5.6	68.5 $\pm$ 13.6	$K=4.07$, $p=0.25$
Braak and Braak (IV:V:VI)	71	1:7:21	0:1:14	2:2:1	5:4:13	$\chi^2=15.5$, $p=0.016^b$
Thal phase (3:4:5)	68 ^a	1:2:25	0:0:15	0:2:3	1:3:16	$\chi^2=14.6$, $p=0.27$
TDP43 (neg:pos)	49	14:7	5:6	3:2	3:9	$\chi^2=5.6$, $p=0.13$
ApoE4 allele (neg:pos)	65	15:12	6:7	1:4	5:15	$\chi^2=5.5$, $p=0.14$

Significant *p*-values are labeled in bold

Age at onset/death and disease duration are presented as mean $\pm$ first standard deviation

K Kruskal–Wallis test, χ^2 2 Chi-squared test, *AD* Alzheimer's disease, *PD* Parkinson's disease, *avail* available, *neg* negative, *pos* positive, *pred* predominant

^aThe three missing cases have a Thal phase ≥ 3

^bBraak and Braak staging was significantly different between α Syn– and α Syn + B ($\chi^2=8.7$, $p=0.013$), and α Syn + A and α Syn + B ($\chi^2=11.5$, $p=0.003$)

Table 3 Comparison of the α -syn-covered area between α Syn + vs. α Syn– cases with multiple linear regression controlling for age and sex and correction for false discovery rate

Region cluster	n (α Syn–)	n (α Syn +)	Median [IQR] [%] of α Syn– cases	Median [IQR] [%] of α Syn + cases	β , <i>p</i> -value (age, sex corrected)
Cortical	73	348	0.001 [0.0004; 0.003]	0.09 [0.008; 0.48]	$\beta=0.009$, $p=0.004$
Subcortical	22	97	0.001 [0.0001; 0.003]	0.06 [0.015; 0.35]	$\beta=0.003$, $p=0.026$
Hippocampal	30	176	0.0006 [0.0002; 0.002]	0.17 [0.017; 0.61]	$\beta=0.005$, $p=0.004$
Amygdala–entorhinal	54	70	0.0013 [0.0002; 0.006]	0.67 [0.30; 1.4]	$\beta=0.013$, $p<0.001$
Brainstem	36	72	0.0025 [0.0007; 0.006]	0.19 [0.014; 0.72]	$\beta=0.005$, $p=0.004$

Significant *p*-values and the highest median α -syn-covered area of the α Syn + group are labeled in bold

ID subject ID, *IQR* interquartile range

subject ID, only the difference in the amygdala–entorhinal region remained significant, indicating a strong difference in the amygdala (Table S4). Comparing the α -syn load of α Syn + with α Syn– cases in 28 brain regions separately under correction of age and sex, there was a significantly higher α -syn-covered area in the substantia nigra ($p=0.005$), amygdala ($p=0.005$), entorhinal cortex ($p=0.023$), and olfactory bulb ($p=0.023$), suggesting these regions as a focus of α -syn co-pathology in AD (Table S5). Other brain regions, e.g., the hippocampus and insula cortex, are also affected. However, probably due to the small absolute numbers, the *p*-values were not statistically significant for other brain regions.

Comparing α -syn-positive subgroups with α Syn– cases, all subgroups showed a comparable age at clinical onset, disease durations, and age at death (Table 2 and Fig. S3). Most of the α Syn + A (67%) and α Syn + C (64%) cases were clinically diagnosed with Alzheimer's disease (Fig. S4), suggesting AD typical symptoms even with Lewy co-pathology. In contrast, two out of five (40%) α Syn + B cases were diagnosed with Alzheimer's disease and 40% with Parkinson's disease, indicating relatively dominant parkinsonian symptoms in the α Syn + B subgroup. Regarding sex distribution, there was a female preponderance in α Syn + A; however, it did not reach significance ($p=0.28$). There was a trend toward younger age at death in α Syn + C, with a mean age

of 68.5 years (± 13.6 years standard deviation) in comparison with 76.5 ± 9.2 years in $\alpha\text{Syn} + \text{A}$, 76.6 ± 5.6 years in $\alpha\text{Syn} + \text{B}$, and 73.7 ± 10.5 years in $\alpha\text{Syn}-$ cases. Although this finding did not reach significance ($p=0.25$) and there was broad variability between cases, this observation suggests a negative association between cortically spread $\alpha\text{-syn}$ pathology in AD and survival. The Braak and Braak staging distribution was shifted toward lower Braak and Braak stages in $\alpha\text{Syn} + \text{B}$, which reached significance when comparing $\alpha\text{Syn}-$ and $\alpha\text{Syn} + \text{B}$ ($p=0.013$), as well as between $\alpha\text{Syn} + \text{A}$ and $\alpha\text{Syn} + \text{B}$ ($p=0.003$). There was no significant difference regarding the Thal phases ($p=0.27$). Where TDP43 information was available, two-thirds of the $\alpha\text{Syn}-$ cases were also TDP43 negative, while three-quarters of the $\alpha\text{Syn} + \text{C}$ subgroup were TDP43 positive. Performing a Chi-squared test over these groups, there was also no significant difference ($p=0.13$). Regarding the presence or absence of the ApoE4 allele, 75% of the $\alpha\text{Syn} + \text{C}$ cases had at least one ApoE4 allele, while it was more balanced in $\alpha\text{Syn}-$ and $\alpha\text{Syn} + \text{A}$ cases, although these group comparisons did not reach significance in a Chi-squared test ($p=0.14$).

To confirm that the $\alpha\text{-syn}$ distribution subgroups vary in their $\alpha\text{-syn}$ distributions, we applied multiple linear regression controlling for specific region names, sex, and age. Detailed results are presented in Fig. 2 and Tables S8 and S11. In pairwise tests, all groups are significantly different from each other in their $\alpha\text{-syn}$ load across cortical regions, with the highest $\alpha\text{-syn}$ load in $\alpha\text{Syn} + \text{C}$ and, after a large gap, $\alpha\text{Syn} + \text{B}$ in second place. $\alpha\text{Syn} + \text{C}$ and, to a lesser extent, $\alpha\text{Syn} + \text{B}$ show significantly higher subcortical $\alpha\text{-syn}$ load than $\alpha\text{Syn}-$ cases. $\alpha\text{Syn} + \text{C}$ significantly shows the highest hippocampal and amygdala–entorhinal $\alpha\text{-syn}$ load, much higher than the actual amygdala–entorhinal predominant $\alpha\text{-syn}$ subgroup $\alpha\text{Syn} + \text{A}$. $\alpha\text{Syn} + \text{B}$ and $\alpha\text{Syn} + \text{C}$ show higher brainstem $\alpha\text{-syn}$ loads than subgroup $\alpha\text{Syn} + \text{A}$. Within $\alpha\text{Syn} + \text{A}$, the highest $\alpha\text{-syn}$ load is in the amygdala and lower in other brain regions. $\alpha\text{Syn} + \text{B}$ shows the highest $\alpha\text{-syn}$ levels in the brainstem with low values in other brain

regions, affirming its definition. Interestingly, $\alpha\text{Syn} + \text{C}$ manifests with an $\alpha\text{-syn}$ amygdala predominance next to high deposit loads in some cortical regions, and often a lower but still high amount in other brain regions. The high deposit load in the amygdala in $\alpha\text{Syn} + \text{C}$ suggests a general $\alpha\text{-syn}$ sensitivity of the amygdala in AD, independent of the exact $\alpha\text{-syn}$ distribution type. In total, the identified distribution patterns propose the presence of distinct pathological $\alpha\text{-syn}$ accumulation features with overlaps, e.g., in the amygdala.

Tau load in relation to $\alpha\text{-syn}$ distribution

According to the inclusion criteria of Braak and Braak stage $\geq \text{IV}$, all AD cases showed marked tau pathology. The most affected area was the amygdala–entorhinal region, followed by the hippocampal region and the cortical region in third place (Table 4). There was a low tau-covered area in the brainstem and subcortical areas. To examine potential associations between tau and $\alpha\text{-syn}$ loads, we compared the tau-covered area of $\alpha\text{Syn}-$ vs. $\alpha\text{Syn} +$ cases with multiple linear regression, correcting for the specific region name, age, and sex. Interestingly, there was no significant effect of $\alpha\text{-syn}$ presence on tau load in any brain region cluster (Fig. 3, Table 4), suggesting independent accumulation of $\alpha\text{-syn}$ and (AT8-) hyperphosphorylated tau.

As additional control analyses, we conducted multiple linear regression without correction for sex and age or with additional correction for ApoE4. Following the previous analysis, there was no significant difference regarding the tau load between $\alpha\text{Syn}-$ and $\alpha\text{Syn} +$ groups in all region clusters. Furthermore, applying linear mixed-effects models with correction for age, sex, and a random factor for subject ID also yielded no significant difference (Table S4). Comparing the tau load of $\alpha\text{Syn} +$ vs. $\alpha\text{Syn}-$ cases in 28 brain regions separately under correction of age and sex, there was no significant difference (Table S6). These findings support a theory of tau accumulation that is independent from $\alpha\text{-syn}$ deposits.

Table 4 Comparison of the tau-covered area between $\alpha\text{Syn} +$ vs. $\alpha\text{Syn}-$ cases with multiple linear regression controlling for age and sex and correction for false discovery rate

Region cluster	n ($\alpha\text{Syn}-$)	n ($\alpha\text{Syn} +$)	Median [IQR] [%] of $\alpha\text{Syn}-$ cases	Median [IQR] [%] of $\alpha\text{Syn} +$ cases	β , p-value (age, sex corrected)
Cortical	216	355	14.4 [7.7; 23]	13.2 [5.3; 23.1]	$\beta = -0.012$, $p = 0.19$
Subcortical	39	72	1.5 [0.6; 4]	1.7 [0.6; 5.6]	$\beta = -0.003$, $p = 0.72$
Hippocampal	133	222	19.8 [13.1; 27.5]	18.9 [10.4; 27.3]	$\beta = -0.017$, $p = 0.19$
Amygdala–entorhinal	42	63	26.3 [18.3; 33]	19.8 [12; 30.6]	$\beta = -0.043$, $p = 0.12$
Brainstem	35	55	2.4 [1.7; 3.6]	1.9 [0.3; 3]	$\beta = -0.002$, $p = 0.72$

The highest median tau covered areas of $\alpha\text{Syn} +$ and $\alpha\text{Syn}-$ groups were labeled in bold
ID subject ID, IQR interquartile range




Fig. 3 Tau load and distribution in Alzheimer's disease. **a** Median tau-covered area of each α -syn distribution group and subgroup. **b** Comparison of the tau-covered area between α Syn- and α Syn+ groups. **c** Comparison of the tau-covered area between α Syn- and α Syn+A (amygdala predominant), α Syn+B (brainstem predominant), α Syn+C (cortical) α -syn-positive subgroups. Statistics in

b and **c** were calculated with multiple linear regression across region clusters, controlling for region names, age, and sex, and false discovery rate correction. Boxplots complemented with scatter dots for female and male patients are available in the supplementary Fig. S7. LC locus coeruleus, OB olfactory bulb

To examine whether tau distribution varies between α -syn-positive subgroups, we performed multiple linear regression controlling for specific region names, age, and sex (Fig. 3, Tables S9 and S11). After FDR correction, there was a significantly decreased tau load in α Syn+B compared to α Syn- cases in cortical ($p < 0.001$), hippocampal ($p < 0.001$), and amygdala-entorhinal regions ($p = 0.021$). Furthermore, but only with correction for age and sex, there was a significantly higher tau load in α Syn+A than in α Syn- cases across cortical regions

($p = 0.004$), indicating a positive association between α -syn in the amygdala and cortical tau accumulation. On the other hand, there was a significantly lower tau load in α Syn+C than in α Syn- cases across cortical regions ($p = 0.022$), which was also only evident when controlling for age and sex, suggesting a relatively lower cortical tau load at death when cortical α -syn load is apparent. These findings were comparable with additional statistical correction for ApoE4 carriage, except for the lower tau load of α Syn+B in the amygdala-entorhinal region.

A β load in relation to α -syn distribution

The analyzed AD cases showed marked A β pathology, predominantly corresponding to Thal phase 5 (Table 1). The most affected areas were the parietal, frontal, and temporal cortices, followed by the amygdala, hippocampal, subcortical, and brainstem areas, which were impacted to a markedly lesser extent (Fig. 4, Table 5; refer to Table S7 for results per region). To examine potential associations between A β and α -syn loads, we compared the A β -covered area of

α Syn– vs. α Syn+ cases with multiple linear regression, correcting for the specific region name, age, and sex. There was a significantly higher A β load in cortical brain regions of α Syn+ cases (Fig. 4, Table 5), suggesting an association of cortical A β with α -syn load.

As control analyses, we conducted multiple linear regression without correction for sex and age. Again, there was a significant difference regarding the A β load between α Syn– and α Syn+ groups in cortical regions (Table S4). Additionally, there were significantly higher A β covered




Fig. 4 Amyloid beta (A β) load and distribution in Alzheimer's disease. **a** Median A β -covered area of each α -syn distribution group and subgroup. **b** Comparison of the A β -covered area between α Syn– and α Syn+ groups. **c** Comparison of the A β -covered area between α Syn– and α Syn+ A (amygdala predominant), α Syn+ B (brainstem predominant), and α Syn+ C (cortical) α -syn-positive subgroups. Statistics in

b and **c** were calculated with multiple linear regression across region clusters, controlling for region names, age, and sex, and false discovery rate correction. Boxplots complemented with scatter dots for female and male patients are available in the supplementary Fig. S8. LC locus coeruleus, OB olfactory bulb

Table 5 Comparison of the A β -covered area between α Syn+ vs. α Syn– groups with multiple linear regression controlling for age and sex and correction for false discovery rate

Region cluster	n (α Syn–)	n (α Syn+)	Median [IQR] [%] of α Syn– cases	Median [IQR] [%] of α Syn+ cases	β , p -value (age, sex corrected)
Cortical	149	288	3.9 [2.2; 6]	5.4 [3.0; 9.7]	$\beta=0.017$, $p=0.003$
Subcortical	20	93	0.5 [0.2; 0.9]	1.5 [0.4; 3.3]	$\beta=0.012$, $p=0.09$
Hippocampal	98	226	0.9 [0.2; 1.8]	1.2 [0.3; 3.5]	$\beta=0.007$, $p=0.09$
Amygdala–entorhinal	16	31	2.4 [1.5; 2.9]	1.5 [0.9; 3.3]	$\beta=-0.002$, $p=0.86$
Brainstem	26	32	0.7 [0.3; 1.3]	0.7 [0.3; 1.6]	$\beta<-0.001$, $p=0.86$

Significant p -values and the highest median A β -covered area of α Syn– and α Syn+ groups were labeled in bold

ID subject ID, IQR interquartile range

areas in the subcortical and hippocampal regions, suggesting a positive association between A β and α -syn across regions. Supplementing the multiple linear regression model with ApoE4 next to sex, age, and region name, the cortical A β load showed a trend but was not significantly different ($p=0.077$). In a further control analysis, applying linear mixed-effects models with correction for age, sex, and a random factor for subject ID, there was also no significant difference, probably due to overcorrection (Table S4). Regarding the 28 brain regions separately, the A β load was higher in the α Syn+ vs. α Syn– group in the occipital sulcus, the insula cortex, and the parahippocampal gyrus; however, these effects did not remain significant after FDR correction or after correction for age and sex (Table S7). Thus, the increase of the A β load in α Syn+ AD cases becomes particularly apparent when multiple regions are considered in one analysis; it is mostly evident in cortical areas, and the effect is partly explained by ApoE4 carriage.

To examine whether the increased A β load can be attributed to specific α -syn-positive subgroups, we applied multiple linear regression controlling for region names, age, and sex (Fig. 4, Table S11). After FDR correction, there was a significantly increased A β load in α Syn+ A compared to α Syn– cases across cortical regions ($p=0.037$) and subcortical regions ($p=0.048$). Additionally, there was a significantly increased A β load in α Syn+ C compared to α Syn– ($p=0.01$) across cortical regions, suggesting that the finding described above of more cortical A β in α Syn+ cases is mainly driven by α -syn subgroups α Syn+ A and α Syn+ C. With additional correction for ApoE4 carriage, there was a significantly higher A β load in the cortical regions of the α Syn+ A vs. α Syn– ($p=0.023$) and α Syn+ B ($p=0.0024$) and in the hippocampal region of α Syn+ A vs. α Syn+ C ($p=0.010$), supporting the notion of a particularly higher A β load in α Syn+ A.

Regarding the theory that depositional patterns can spread further, we plotted the values of mean cortical A β load and α -syn load in the amygdala against each other (Fig. S12). Subgroup α Syn+ C appears to encompass subgroups

α Syn+ A and α Syn+ B, making a development from α Syn+ A and α Syn+ B to α Syn+ C conceivable.

α -syn co-pathology in relation to age, sex, and ApoE genotype

We examined the association of α -syn co-pathology in AD with age at death, sex, and ApoE status (Fig. 5). Although there is a recruitment bias in the cohort, comparing features within this cohort might provide further insight. In detail, we applied multiple linear regression with α -syn-covered area as the target variable and sex as a predictor variable across region clusters, controlling for the specific region names. An increased α -syn load in cortical regions in female vs. male cases ($\beta=-0.0049$, $p=0.038$) did not remain significant after FDR correction ($p=0.19$) with comparable results after additionally correcting for age. Cortical, region-wise comparison within the α Syn+ C group suggests that this finding is mainly outlier driven in the female group (Fig. S5) and a larger cohort would be needed for further clarification. The α -syn load also did not differ between female and male cases in other brain regions.

To examine the association with age, we defined three age groups: < 65 years at death (< 65), 65 to < 75 years (65–75), 75 years or older (≥ 75). Thereby, it should be noted that all cases pertain to advanced stages of AD. We applied multiple linear regression with α -syn-covered area as the target variable and age group as a predictor variable across region clusters, controlling for specific region names. Before FDR correction, there was a significantly higher cortical α -syn load in AD patients 65–75 years old compared with those < 65 years ($\beta=0.007$, $p=0.033$). This result was not significant after FDR correction or correction for sex. Interestingly, there was a significantly lower α -syn load in the hippocampal region in AD patients 65–75 years old compared with those < 65 years ($\beta=-0.0033$, $p=0.030$), which was also significant after correction for sex but not after FDR correction. The amygdala–entorhinal α -syn load was significantly lower in patients ≥ 75 years old compared with




Fig. 5 α -syn load split up by **a** sex, **b** age at death, and **c** ApoE genotype in Alzheimer's disease cases. Statistics were calculated with multiple linear regression across region clusters, correcting for specific region names and false discovery rate correction. Results with

age or sex correction are presented in the main text. Boxplots complemented with scatter dots for female and male patients are available in the supplementary Fig. S9. ApoE4 means that at least one ApoE4 allele is apparent

those 65–75 years ($\beta = -0.0078$, $p = 0.033$), which was also significant after correction for sex but not after FDR correction. In total, these results suggest that α -syn co-pathology in general appears independent of patient age, but a higher hippocampal and amygdala–entorhinal α -syn load might be associated with a younger age at death to a certain extent. Another explanation could be that younger patients with initiated protein deposition cascades can accumulate higher

α -syn loads in the hippocampus and amygdala until death, maybe due to fewer life-limiting comorbidities. However, this trend was not reflected in cortical regions.

To evaluate the association of α -syn load in AD with the ApoE genotype, we compared AD cases with at least one ApoE4 allele to cases without ApoE4. Again, multiple linear regression was applied with α -syn load as the target variable and ApoE status as the predictor variable across region

clusters, controlling for the specific region names. The cortical α -syn load of ApoE4 carriers was significantly lower ($\beta = -0.0055$, $p = 0.034$), but did not remain significant after FDR correction or correction for sex and age. On the other hand, there was a significantly higher α -syn load in the hippocampal ($\beta = 0.0045$, $p = 0.0019$) and amygdala–entorhinal regions ($\beta = 0.0066$, $p = 0.038$) of ApoE4 carriers, which was significant after correction for age and sex, but only the difference in the hippocampal regions stayed significant after FDR correction ($p = 0.009$ without and $p = 0.016$ with correction for age and sex). These results suggest ApoE4 as a risk factor for higher hippocampal and putatively amygdala–entorhinal α -syn load, which in turn might be associated with a younger age at death.

A β and tau load in relation to age, sex, and ApoE genotype

Additionally, we investigated the relation of age, sex, and ApoE genotype regarding tau and A β load (Figs. S10 and S11). In parallel to the α -syn analysis, the cohort selection is biased by voluntary donation, but an examination within the cohort might still be insightful. We applied multiple linear regression with tau or A β -covered area as the target variable and sex, age, or ApoE as predictor variables across region clusters, controlling for the specific region names and FDR correction. There was a significantly higher tau load in male patients in the hippocampal ($\beta = 0.029$, $p = 0.009$) and amygdala–entorhinal regions ($\beta = 0.06$, $p = 0.009$), which was also significant after correction for age ($p = 0.022$, respectively). Conversely, the A β load was significantly higher in female patients in cortical ($\beta = -0.022$, $p < 0.001$) and hippocampal regions ($\beta = -0.013$, $p < 0.001$), which was significant after correction for age. These findings suggest a sex imbalance toward tau in male and A β in female cases.

Regarding different age groups, all with advanced disease stages, there was a significantly lower cortical tau load in the oldest group (≥ 75 years at death) than in the younger age groups, < 65 ($\beta = -0.024$, $p < 0.001$) and $65\text{--}75$ ($\beta = -0.024$, $p = 0.038$). Both findings were significant after correction for sex. In line with this observation, there was a significantly higher A β load in the youngest age group, < 65 years, than in $65\text{--}75$ years old patients in the hippocampal regions ($\beta = -0.016$, $p < 0.001$) and in brainstem regions in the $65\text{--}75$ ($\beta = -0.015$, $p = 0.007$) and ≥ 75 years cases ($\beta = -0.007$, $p = 0.0027$). The findings remained significant after correction for sex and suggest a higher deposit load in younger AD cases at death.

Concerning the presence of at least one ApoE4 allele, there was no significant association with tau covered areas, but with further age and sex correction, there was a significantly decreased tau load in ApoE4 carriers in cortical ($\beta = -0.020$, $p = 0.03$), hippocampal ($\beta = -0.026$, $p = 0.03$),

and amygdala–entorhinal regions ($\beta = -0.043$, $p = 0.049$). Regarding A β , there was a higher A β load in the cortical regions of ApoE4 carriers ($\beta = 0.019$, $p = 0.001$), also significant after age and sex correction. This finding coincides with the high A β load in the α Syn + C cases with a relatively high proportion of ApoE4 carriers. ApoE4 might be related to disseminated α -syn deposition and to a higher cortical A β load with a speculative causal relationship.

Discussion

Quantifying A β , tau, and α -syn load across brain regions in 72 Alzheimer's disease (AD) patients, 60% of the cases showed detectable Lewy pathology. While the exact ratios vary between cohorts due to selection and recruitment biases [4, 30, 76], the main findings and descriptions of frequently pronounced co-pathologies are reinforced across studies. The α -syn deposit load predominates in the amygdala, but is heterogeneous in the cortical and brainstem regions, which can be subgrouped into several distribution patterns. The extent of A β and tau load varies between these α -syn subgroups, suggesting direct and indirect protein interactions and confounding factors.

Alpha-synuclein distribution patterns: separate groups in a progressive process

Approaching previously specified Lewy body pathology patterns [5, 51], we assigned α -syn-positive (α Syn +) AD cases to three subgroups by thresholding the regional α -syn-covered areas. The biggest subgroup, α Syn + C, showed disseminated α -syn pathology at least somewhere in the cortex and a high amount in the amygdala. The second largest subgroup, α Syn + A, exhibits an amygdala-predominant α -syn pattern without significant Lewy pathology in the cortex. Finally, few AD cases mainly had α -syn deposits in the brainstem, α Syn + B, more specifically in the substantia nigra and to a lesser extent in the locus coeruleus. This classification approximates previously described amygdala-predominant and disseminated α -syn distribution patterns in AD [76].

While α Syn + A presents with Lewy pathology in the amygdala but not in the brainstem, α Syn + B shows higher loads in the brainstem than in the amygdala. Thus, α Syn + A and α Syn + B seem to be separated from each other. The prevalence of α Syn + B was relatively low in the study cohort, but might still be artificially increased due to voluntary brain donation. As the case collection is not population representative, it remains speculative if α Syn + B equals a random coexistence of AD and Parkinson's disease, with a prevalence of Parkinson's disease of around 1.6% in Europe between 70 and 79 years [59].

Focusing on the α -syn loads across regions, α Syn + A and α Syn + B can theoretically develop into the pattern of α Syn + C, supporting the theory of spreading Lewy pathology as far as these conclusions are possible from non-longitudinal autopsy data [1, 10]. This theory might be further supported by the finding of more α Syn + C cases in comparison with α Syn + A or α Syn + B patterns in genetic cases and cases with young age at symptom onset. Patients with AD-related mutations frequently showed an α Syn $^-$ pattern (47%) or a disseminated co-pathology, α Syn + C (37%), but much less common intermediate α Syn + A (11%) and α Syn + B (5%) states. Although numbers are small, this distribution supports the hypothesis that strong genetic A β drive may accelerate or alter the trajectory of α -synuclein propagation. In this framework, AD-related mutations could hasten the transition from early phases (α Syn + A/ α Syn + B) into widespread cortical α -synuclein deposition (α Syn + C), within the same disease duration. Conversely, some mutation carriers remain α Syn $^-$ despite dominant A β pathology. Thus, A β - and α -synuclein-driven processes may arise separately but converge in a subset of patients, shaping overall disease tempo and severity.

Lacking olfactory bulb tissue in a high number of cases did not allow for detection of rare cases with olfactory only Lewy pathology described by Attems et al. [5]. Additionally, a bigger cohort would be needed to detect a limbic-predominant subgroup, which is probably currently included as part of the cortical subgroup.

It is noticeable that the amygdala was the most affected region by α -syn deposits in AD, followed by the CA2 region of the hippocampus. This finding is apparent across subgroups except for some brainstem-predominant cases. While the amygdala's predominance of α -syn in AD was described before [4, 30, 76], the reasons for the region's sensitivity are still under discussion [56]. Nevertheless, distinct Lewy pathology distributions described in DLB [51, 52] are also present in AD as a spectrum of co-pathology patterns related to partly overlapping clinical symptoms [18, 77].

Tau load varies between α -syn subgroups

Comparing the (AT8-) hyperphosphorylated tau load of α Syn + vs. α Syn $^-$ AD cases with multiple linear regression correcting for age and sex, there was no significant difference. This finding is consistent with previous immunohistochemical analyses showing comparable tau loads in AD with and without Lewy body co-pathology [29]. However, comparing α Syn $^-$ cases with three α -syn-positive subgroups, there were significant differences, emphasizing the importance of patient stratification. We found a significantly increased cortical tau load in the amygdala-predominant α -syn subgroup, α Syn + A, compared to the α Syn $^-$ group, while the cortical tau load was lower in α Syn + B and

α Syn + C. These results demonstrate a variable association between α -syn and tau load depending on the α -syn distribution and highlight the importance of statistical adjustment for age and sex.

Especially within the amygdala, some neurons contain Lewy bodies and neurofibrillary tangles concomitantly [43, 65]. A co-localization was also described in astrocytes [29]. Arai and colleagues argue that not all α -syn aggregations are Lewy bodies; on the other hand, the tau load might impact which regions develop more Lewy bodies [4]. The molecular relationship between α -syn and tau and its consequences is still under discussion, with several studies claiming adverse interactions between these proteins: α -syn and tau share molecular similarities and overlap in their radius of action [55]. Specific α -syn and tau isoforms show heightened binding affinities toward each other [27, 61]. α -syn plays a role in tau phosphorylation, and the proteins promote each other's fibrillization [32, 36, 55]. There are further hints of α -syn driving tau accumulation through genetic elements responsible for higher baseline SNCA expression [69]. Ultimately, subjects with a positive cerebrospinal fluid α -syn seed aggregation assay had higher tau PET signals [28].

The increased cortical tau load in α Syn + A fits the hypothesis of mutual α -syn–tau interactions. The brainstem-predominant α -syn pattern seems to drop out of general patterns like amygdala predominance and therefore might correspond to separate mechanisms. The cortical α -syn subgroup showed a decreased tau load with a tendency for a younger age at death [58]. An explanation could be that AD with disseminated α -syn pathology is fatal before the tau load reaches levels as high as in α -syn-negative AD cases. α -syn may add to the toxic effect of hyperphosphorylated tau, so clinical relevance is already reached at a lower tau level.

A β load is increased in α -syn subgroups

Comparing the A β load of α Syn + vs. α Syn $^-$ AD cases with multiple linear regression correcting for age and sex, there was an increased A β load in α -syn-positive cases attributable to α Syn + A and partly α Syn + C subgroups. There was also a trend of higher A β load in subcortical and hippocampal regions, supporting a general tendency. Such a positive association between A β and α -syn was partly described before in the clinical spectrum of AD and dementia with Lewy bodies [77] and the other way around in Lewy body dementia with A β co-pathology [54]. This finding also accords with semiquantitative studies revealing a strong association between AD pathology and amygdala-predominant α -syn deposition, while there was no such effect in a caudo-rostral α -syn co-pathology group [62]. On a more mechanistic level, several studies support an association between A β and α -syn [47]. Nuclear magnetic resonance spectroscopy

suggests the interaction of A β with membrane-associated α -syn [46]. In vitro and in vivo experiments support the hypothesis that A β promotes α -syn aggregation [38, 48]. However, this hypothesis did not apply for specific regions; e.g., the A β load was not increased in the amygdala of the amygdala-predominant or cortical α -syn subgroups. These findings suggest a more complex interplay of A β and α -syn, as well as tau to a certain extent, involving multiple factors, rather than local correlations.

Recent studies align with this interpretation. Clinical and imaging studies demonstrated that α -syn co-pathology is more prevalent in advanced AD and accelerates amyloid-driven tau aggregation, thereby worsening clinical decline [2, 28]. Struëbing et al. [69] further showed that AD cases with cortical α -synuclein carry higher Parkinson's disease polygenic risk as well as increased AD age-at-onset risk, indicating contributions from both Parkinson's disease (PD) and AD-related susceptibility factors. Together, these findings support a model in which A β , tau, and α -synuclein interact along partially distinct routes that converge in some patients, driving aggressive cortical disease and underscoring the importance of genetic and pathological stratification in future studies.

Association of ApoE4, sex, and age with AD and α -syn co-pathology

Comparing epidemiological data in terms of age, sex, and ApoE genotype among α -syn groups and subgroups in AD, no significant differences were apparent. Although the study cohort is limited by voluntary recruitment, the finding is in line with previous observations [63]. However, regarding the ApoE genotype, there was a trend toward more ApoE4 carriers in the partition with α -syn deposits, more specifically in the α Syn + C cases. Comparing ApoE4 carriers with no ApoE4 carriers using multiple linear regression across regions, the ApoE4 allele was associated with a significantly higher α -syn load in the hippocampus. Additionally, the ApoE4 allele was associated with a higher cortical A β load and a lower tau load in several brain regions after age and sex correction. These results are supported by literature, presenting ApoE4 as a risk factor for AD [24, 44] with the specific effects on A β and tau differing between studies, approaches, and brain regions [6, 23, 31, 50, 68]. ApoE4 is also a risk factor for DLB [12] and increased α -syn levels in the cerebrospinal fluid of AD patients [75].

Regarding sex differences, there was a trend toward more female subjects in the partition with α -syn deposits, mostly apparent in the α Syn + A subgroup. Examining the association of the α -syn load in AD with sex across brain regions using multiple linear regression, there was no significant difference, suggesting that male and female patients show comparable α -syn load. This is in line with

more or less sex-balanced cohorts in DLB [60]. Besides, we observed an increased A β load in female patients and an increased tau load in male patients predicted by multiple linear regression across brain regions. These findings align with the observations in a transgenic mouse model [34]. Several studies in humans found increased A β and tau load in women [8, 26, 57]. The discrepancy in the tau results may be attributable to differences in age distributions and analytical approaches.

The AD subgroup with disseminated cortical α -syn tended to have a lower mean age at death, consistent with previous observations [58]. Including all AD cases, the α -syn load did not differ significantly between age groups tested with multiple linear regression. This is in line with observations that α -syn co-pathology is common in sporadic, but also in younger genetic cases [43] and, thus, cannot be explained by simple accumulation with age. Comparing A β and tau load in AD between different ages with multiple linear regression across brain regions, the A β and tau load were focally increased in patients with a younger age at death. These results are partly in accordance with previous PET analyses which showed increased tau accumulation in younger A β -positive subjects, while A β deposition was faster in older cases [68]. In agreement with this finding, a PET study by Lowe et al. reported increasing tau load with age in cognitively unimpaired samples, but a higher tau load in younger cognitively impaired patients, suggesting higher loads in younger-onset AD [45]. In line with our results, there was also a higher A β load described in PETs of early-onset AD cases in comparison with late-onset cases [40].

In summary, subject to limited brain donation recruitment, ApoE4 is a risk factor for higher α -syn and A β load in AD. The exact causal chain remains speculation: ApoE4 might indirectly increase the α -syn load via increased A β and maybe tau loads [20] and directly via altered degradation of α -syn [53]. In particular, ApoE4 carriage statistically explained the association between α Syn + C and cortical A β load, but not the association between α Syn + A and cortical A β load, suggesting ApoE4 as a confounding factor and additional potentiating effects between deposit types. A β and tau load were partly increased in younger patients with dementia compared to older cases. This might be explained by the A β -related, genetically driven cases in our cohort, putatively together with higher body reserves in younger people. Alpha-synuclein co-pathology appears across all ages. The findings emphasize the importance of control for age and sex in research analyses, and especially in clinical diagnostics and therapies [25]. However, the results also show a pronounced complexity of the relationships. Despite subdivision into subgroups, there is often a large variance between the cases. Normative approaches and larger cohorts can help narrow down other factors that influence the extent of pathologies at an individual level.

Strengths and limitations

A strength of this study is the large size of the dataset, comprising many brain regions analyzed in up to three immunohistochemical stains. The region annotation was standardized, and the deposit detection was automated to gain reliable and objective quantifications. The obtained segmentations can also serve as initial data for further morphology-based categorization of deposits. Despite this extensive approach, the study has several limitations. First, the dataset could be even larger and more complete regarding the availability of α -syn stains across brain regions to be more sensitive for smaller α -syn subgroups and to reduce the potential bias of missing stains. For example, a pure olfactory α -syn subgroup was not detected in our cohort, probably because of its rare appearance and incomplete tissue embedding in a subset of cases; additionally, the sex, age, and ApoE4 evaluation are limited by a relatively small and probably not representative cohort for epidemiological analyses. For precise proportions, population-based studies are necessary, and cross-ethnic datasets are needed. Second, the region annotation protocol focuses on small rectangles of regions of interest instead of whole slide images, which could miss variability within each block, e.g., neuronal degeneration is not homogeneous within the substantia nigra [21], which exceeds the approach of this article. However, this reduction helped to limit the amount of large-sized data and led to a reasonable consumption of computational power. Third, this study focused on specific antibody clones, namely clone 42 for α -syn, clone 4G8 for A β , and clone AT8 for tau staining. These antibodies are typically applied in diagnostics but are restricted to specific targets, e.g., AT8 sticks to tau with defined phosphorylation sites. Further studies are needed for other epitopes and to take other co-pathologies like TDP43 deposits into account. Finally, this analysis approached different AD neuropathological subgroups. However, the dataset exclusively represents advanced stages of AD, and the α -syn subgrouping did not fully explain the heterogeneity in tau and A β load. As a correlative post-mortem study, causal conclusions remain speculative.

Conclusion

Quantifying neuropathological deposits in Alzheimer's disease, we found α -syn co-pathology in more than half of the cases across age groups with a tendency toward female patients and an association with the ApoE4 allele. Assigning three distinct α -syn distribution groups, the common amygdala-predominant and cortical α -syn patterns were associated with an increased cortical A β load, while tau load varied between these groups. To conclude, next to age, sex, and ApoE, the α -syn distribution pattern is associated

with distinct A β and tau loads with potential therapeutic relevance in immunization therapies.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00401-025-02952-w>.

Acknowledgements First, we deeply thank all brain donors and their families for facilitating this research. We are also very thankful to all current and former colleagues of the Neurobiobank Munich, especially A. Obermaier, Anke Jürgensonn, Dr. Thomas Arzberger, Dr. Otto Windl, Dr. Benjamin Englert, and Dr. Norbert Buresch for their elaborate organization, processing, and diagnostics. We would also like to thank Michael Schmidt for his help with immunohistochemistry and slide scanning.

Author contributions Study concept and supervision: AN, PF, FLS, JH; data collection and data banking: SR, VR, JH; methodology: AN, DW, SP, PF, FLS; formal analysis: AN, SP, PF; drafting the manuscript: AN, PF, FLS, JH; revising the manuscript: AN, DW, SP, SR, VR, PF, FLS, JH.

Funding Open Access funding enabled and organized by Projekt DEAL. AN was supported by travel grants from the Alzheimer Forschung Initiative e.V. (AFI) and the framework of Munich Cluster for Systems Neurology (SyNergy). FLS is supported by the German Research Foundation (DFG, grant number STR 1537/3–1). This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy-ID 390857198).

Data availability Supporting data, code, and segmentation models applied in this study can be obtained from the corresponding author upon reasonable request. The code to plot colors on brain atlas images is publicly available on GitHub (https://github.com/cor2ni/2D_brain_plot).

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN et al (2019) Unified staging system for Lewy body disorders: clinicopathologic correlations and comparison to Braak staging. *J Neuropathol Exp Neurol* 78:891–899. <https://doi.org/10.1093/jnen/nlz080>
- Almeida FC, Santos A, Jesus T, Coelho A, Quintas-Neves M, Gauthreaux K et al (2025) Lewy body co-pathology in

- Alzheimer's disease and primary age-related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns. *Alzheimers Dement* 21:e14191. <https://doi.org/10.1002/alz.14191>
3. Allen Reference Atlas – Human Brain [brain atlas]. Available from atlas.brain-map.org. 2025.
 4. Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) α -Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. *Brain Res* 888:287–296. [https://doi.org/10.1016/S0006-8993\(00\)03082-1](https://doi.org/10.1016/S0006-8993(00)03082-1)
 5. Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G et al (2021) Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. *Acta Neuropathol* 141:159–172. <https://doi.org/10.1007/s00401-020-02255-2>
 6. Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, Lyoo CH (2020) Effect of APOE ϵ 4 genotype on amyloid- β and tau accumulation in Alzheimer's disease. *Alz Res Therapy* 12:140. <https://doi.org/10.1186/s13195-020-00710-6>
 7. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. *Sci Rep* 7:16878. <https://doi.org/10.1038/s41598-017-17204-5>
 8. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. *Arch Gen Psychiatry* 62:685–691. <https://doi.org/10.1001/archpsyc.62.6.685>
 9. Bassil F, Meymand ES, Brown HJ, Xu H, Cox TO, Pattabhiraman S et al (2020) α -synuclein modulates tau spreading in mouse brains. *J Exp Med* 218:e20192193. <https://doi.org/10.1084/jem.20192193>
 10. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J et al (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. *Acta Neuropathol* 117:613–634. <https://doi.org/10.1007/s00401-009-0538-8>
 11. Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L et al (2024) Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. *Alzheimers Dement* 20:2444–2452. <https://doi.org/10.1002/alz.13658>
 12. Berge G, Sando SB, Rongve A, Aarsland D, White LR (2014) Apolipoprotein E ϵ 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. *J Neurol Neurosurg Psychiatry* 85:1227–1231. <https://doi.org/10.1136/jnnp-2013-307228>
 13. Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS et al (2013) Risk factors for dementia with lewy bodies. *Neurology* 81:833–840. <https://doi.org/10.1212/WNL.0b013e3182a2cbd1>
 14. Borghammer P, Horsager J, Andersen K, Van Den Berge N, Raunio A, Murayama S et al (2021) Neuropathological evidence of body-first vs. brain-first Lewy body disease. *Neurobiol Dis* 161:105557. <https://doi.org/10.1016/j.nbd.2021.105557>
 15. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol* 82:239–259. <https://doi.org/10.1007/BF00308809>
 16. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24:197–211. [https://doi.org/10.1016/S0197-4580\(02\)00065-9](https://doi.org/10.1016/S0197-4580(02)00065-9)
 17. Bucci M, Chiotis K, Nordberg A (2021) Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. *Mol Psychiatry* 26:5888–5898. <https://doi.org/10.1038/s41380-021-01263-2>
 18. Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW (2005) The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. *Neurology* 64:1397–1403. <https://doi.org/10.1212/01.WNL.0000158423.05224.7F>
 19. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC (2010) α -synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* 329:1663–1667. <https://doi.org/10.1126/science.1195227>
 20. Chen Y, Jin H, Chen J, Li J, Găman M-A, Zou Z (2025) The multifaceted roles of apolipoprotein E4 in Alzheimer's disease pathology and potential therapeutic strategies. *Cell Death Discov* 11:312. <https://doi.org/10.1038/s41420-025-02600-y>
 21. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain: II. patterns of loss of dopamine-containing neurons in Parkinson's disease. *Brain* 122:1437–1448. <https://doi.org/10.1093/brain/122.8.1437>
 22. Ding S-L, Royall JJ, Sunkin SM, Ng L, Facer BAC, Lesnar P et al (2016) Comprehensive cellular-resolution atlas of the adult human brain. *J Comp Neurol* 524:3127–3481. <https://doi.org/10.1002/cne.24080>
 23. Emrani S, Arain HA, DeMarshall C, Nuriel T (2020) APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. *Alz Res Therapy* 12:141. <https://doi.org/10.1186/s13195-020-00712-4>
 24. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. *JAMA* 278:1349–1356. <https://doi.org/10.1001/jama.1997.03550160069041>
 25. Ferretti MT, Iulita MF, Cavado E, Chiesa PA, Schumacher Dimech A, Santucci Chadha A et al (2018) Sex differences in Alzheimer disease — the gateway to precision medicine. *Nat Rev Neurol* 14:457–469. <https://doi.org/10.1038/s41582-018-0032-9>
 26. Filon JR, Intorcchia AJ, Sue LI, Vazquez Arreola E, Wilson J, Davis KJ et al (2016) Gender differences in Alzheimer disease: brain atrophy, histopathology burden, and cognition. *J Neuropathol Exp Neurol* 75:748–754. <https://doi.org/10.1093/jnen/nlw047>
 27. Fischer A-L, Schmitz M, Thom T, Zafar S, Younas N, da Silva CS et al (2025) Alpha-synuclein demonstrates varying binding affinities with different tau isoforms. *J Neurochem* 169:e70053. <https://doi.org/10.1111/jnc.70053>
 28. Franzmeier N, Roemer-Cassiano SN, Bernhardt AM, Dehsarvi A, Dewenter A, Steward A et al (2025) Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease. *Mol Neurodegener* 20:31. <https://doi.org/10.1186/s13024-025-00822-3>
 29. van der Gaag BL, Deshayes NAC, Breve JJP, Bol JGJM, Jonker AJ, Hoozemans JJM et al (2024) Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia. *Acta Neuropathol* 147:14. <https://doi.org/10.1007/s00401-023-02657-y>
 30. Gawor K, Tomé SO, Vandenbergh R, Van Damme P, Vandenbulcke M, Otto M et al (2024) Amygdala-predominant α -synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer's disease. *Brain Commun* 6:fcae442. <https://doi.org/10.1093/braincomms/fcae442>
 31. Ghebremedhin E, Schultz C, Thal DR, Rüb U, Ohm TG, Braak E et al (2001) Gender and age modify the association between APOE and AD-related neuropathology. *Neurology* 56:1696–1701. <https://doi.org/10.1212/WNL.56.12.1696>
 32. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. *Science* 300:636–640. <https://doi.org/10.1126/science.1082324>

33. Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α -synuclein immunohistochemistry. *Brain Pathol* 10:378–384. <https://doi.org/10.1111/j.1750-3639.2000.tb00269.x>
34. Hirata-Fukae C, Li H-F, Hoe H-S, Gray AJ, Minami SS, Hamada K et al (2008) Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. *Brain Res* 1216:92–103. <https://doi.org/10.1016/j.brainres.2008.03.079>
35. Jellinger KA (2003) A-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution—a pilot study. *Acta Neuropathol* 106:191–202. <https://doi.org/10.1007/s00401-003-0725-y>
36. Jensen PH, Hager H, Nielsen MS, Højrup P, Gliemann J, Jakes R (1999) α -synuclein binds to Tau and stimulates the protein kinase a-catalyzed Tau phosphorylation of serine residues 262 and 356 *. *J Biol Chem* 274:25481–25489. <https://doi.org/10.1074/jbc.274.36.25481>
37. Klouieva NM, Rademaker MC, Dexter DT, Al-Sarraj S, Seilhean D, Streichenberger N et al (2015) Brainnet Europe's code of conduct for brain banking. *J Neural Transm* 122:937–940. <https://doi.org/10.1007/s00702-014-1353-5>
38. Köppen J, Schulze A, Machner L, Wermann M, Eichentopf R, Guthardt M et al (2020) Amyloid-beta peptides trigger aggregation of Alpha-synuclein in vitro. *Molecules* 25:580. <https://doi.org/10.3390/molecules25030580>
39. Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S et al (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. *Dementia Geriatr Cogn Disord* 26:343–350. <https://doi.org/10.1159/000161560>
40. Lagarde J, Maiti P, Schonhaut DR, Blazhenets G, Zhang J, Eloyan A et al (2025) Amyloid PET in sporadic early- versus late-onset Alzheimer's disease: comparison of the LEADS and ADNI cohorts. *Ann Neurol* 98:236–248. <https://doi.org/10.1002/ana.27233>
41. Lancôt KL, Hahn-Pedersen JH, Eichinger CS, Freeman C, Clark A, Tarazona LRS et al (2024) Burden of illness in people with Alzheimer's disease: a systematic review of epidemiology, comorbidities and mortality. *J Prev Alzheimers Dis* 11:97–107. <https://doi.org/10.14283/jpad.2023.61>
42. Lane CA, Hardy J, Schott JM (2018) Alzheimer's disease. *Eur J Neurol* 25:59–70. <https://doi.org/10.1111/ene.13439>
43. Lippa CF, Fujiwara H, Mann DMA, Giasson B, Baba M, Schmidt ML et al (1998) Lewy bodies contain altered α -synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am J Pathol* 153:1365–1370. [https://doi.org/10.1016/S0002-9440\(10\)65722-7](https://doi.org/10.1016/S0002-9440(10)65722-7)
44. Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol* 9:106–118. <https://doi.org/10.1038/nrneurol.2012.263>
45. Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF et al (2018) Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. *Brain* 141:271–287. <https://doi.org/10.1093/brain/awx320>
46. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between A β peptide and α synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. *Neurochem Res* 31:1153–1162. <https://doi.org/10.1007/s11064-006-9140-9>
47. Marsh SE, Blurton-Jones M (2012) Examining the mechanisms that link β -amyloid and α -synuclein pathologies. *Alzheimers Res Ther* 4:11. <https://doi.org/10.1186/alzrt109>
48. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M et al (2001) β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. *Proc Natl Acad Sci U S A* 98:12245–12250. <https://doi.org/10.1073/pnas.211412398>
49. Mastenbroek SE, Vogel JW, Collij LE, Serrano GE, Tremblay C, Young AL et al (2024) Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α -synuclein pathology. *Nat Commun* 15:5133. <https://doi.org/10.1038/s41467-024-49402-x>
50. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J et al (2018) Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. *Alz Res Therapy* 10:77. <https://doi.org/10.1186/s13195-018-0403-x>
51. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies. *Neurology* 89:88–100. <https://doi.org/10.1212/WNL.0000000000004058>
52. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J et al (2004) Dementia with Lewy bodies. *Lancet Neurol* 3:19–28. [https://doi.org/10.1016/S1474-4422\(03\)00619-7](https://doi.org/10.1016/S1474-4422(03)00619-7)
53. Meskint-Louro LA, Goldman C, Ndayisaba A, Buonfiglioli A, Rooklin RB, Schuldt BR et al (2025) Cholesterol-mediated lysosomal dysfunction in APOE4 astrocytes promotes α -synuclein pathology in human brain tissue. *BioRxiv*. <https://doi.org/10.1101/2025.02.09.637107>
54. Miller RL, Dhavale DD, O'Shea JY, Andruska KM, Liu J, Franklin EE et al (2022) Quantifying regional α -synuclein, amyloid β , and tau accumulation in lewy body dementia. *Ann Clin Transl Neurol* 9:106–121. <https://doi.org/10.1002/acn3.51482>
55. Moussaud S, Jones DR, Moussaud-Lamodièrre EL, Delenclos M, Ross OA, McLean PJ (2014) Alpha-synuclein and tau: teammates in neurodegeneration? *Mol Neurodegeneration* 9:43. <https://doi.org/10.1186/1750-1326-9-43>
56. Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ et al (2018) The amygdala as a locus of pathologic misfolding in neurodegenerative diseases. *J Neuropathol Exp Neurol* 77:2–20. <https://doi.org/10.1093/jnen/nlx099>
57. Nemes S, Logan PE, Manchella MK, Mundada NS, La Joie R, Polsinelli AJ et al (2023) Sex and APOE ϵ 4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. *Alzheimers Dement* 19(S9):S49–63. <https://doi.org/10.1002/alz.13403>
58. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R et al (1998) Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. *Neurology* 51:351–357. <https://doi.org/10.1212/WNL.51.2.351>
59. Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of Parkinson's disease: a systematic review and meta-analysis. *Mov Disord* 29:1583–1590. <https://doi.org/10.1002/mds.25945>
60. Raheel K, Deegan G, Di Giulio I, Cash D, Ilic K, Gnani V et al (2023) Sex differences in alpha-synucleinopathies: a systematic review. *Front Neurol*. <https://doi.org/10.3389/fneur.2023.1204104>
61. Ramirez J, Saleh IG, Yanagawa ESK, Shimogawa M, Brackhahn E, Petersson EJ et al (2024) Multivalency drives interactions of alpha-synuclein fibrils with tau. *PLoS ONE* 19:e0309416. <https://doi.org/10.1371/journal.pone.0309416>
62. Raunio A, Kaivola K, Tuimala J, Kero M, Oinas M, Polvikoski T et al (2019) Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. *Acta Neuropathol* 138:771–782. <https://doi.org/10.1007/s00401-019-02071-3>
63. Robinson JL, Lee EB, Xie SX, Rennett L, Suh E, Bredenberg C et al (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain* 141:2181–2193. <https://doi.org/10.1093/brain/awy146>

64. Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B et al (2021) The development and convergence of co-pathologies in Alzheimer's disease. *Brain* 144:953–962. <https://doi.org/10.1093/brain/awaa438>
65. Schmidt ML, Martin JA, Lee VM-Y, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. *Acta Neuropathol* 91:475–481. <https://doi.org/10.1007/s004010050454>
66. Sengupta U, Kaye R (2022) Amyloid β , tau, and α -synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. *Prog Neurobiol* 214:102270. <https://doi.org/10.1016/j.pneurobio.2022.102270>
67. Silva-Rodríguez J, Labrador-Espinosa MA, Zhang L, Castro-Labrador S, López-González FJ, Moscoso A et al (2025) The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnesic patients. *Brain*. <https://doi.org/10.1093/brain/awaf037>
68. Smith R, Strandberg O, Mattsson-Carlsson N, Leuzy A, Palmqvist S, Pontecorvo MJ et al (2020) The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. *Brain* 143:3805–3815. <https://doi.org/10.1093/brain/awaa327>
69. Struëbing FL, Vecchi TD, Widmann J, Song X, Fierli F, Ruf V, et al (2025). Alpha-synuclein co-pathology in Alzheimer's disease drives tau accumulation 2025.01.24.634706. <https://doi.org/10.1101/2025.01.24.634706>.
70. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A β -deposition in the human brain and its relevance for the development of AD. *Neurology* 58:1791–1800. <https://doi.org/10.1212/WNL.58.12.1791>
71. Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S et al (2016) Pathological α -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. *Acta Neuropathol* 131:393–409. <https://doi.org/10.1007/s00401-015-1526-9>
72. Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB et al (2024) A cross-sectional study of α -synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function. *Alzheimers Dement* 20:5114–5131. <https://doi.org/10.1002/alz.13858>
73. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM (2008) A β inhibits the proteasome and enhances amyloid and tau accumulation. *Neurobiol Aging* 29:1607–1618. <https://doi.org/10.1016/j.neurobiolaging.2007.04.014>
74. Twohig D, Nielsen HM (2019) A-synuclein in the pathophysiology of Alzheimer's disease. *Mol Neurodegener* 14:23. <https://doi.org/10.1186/s13024-019-0320-x>
75. Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I et al (2018) The relevance of cerebrospinal fluid α -synuclein levels to sporadic and familial Alzheimer's disease. *Acta Neuropathol Commun* 6:130. <https://doi.org/10.1186/s40478-018-0624-z>
76. Uchikado H, Lin W-L, DeLucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of α -synucleinopathy. *J Neuropathol Exp Neurol* 65:685–697. <https://doi.org/10.1097/01.jnen.0000225908.90052.07>
77. Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C et al (2015) Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. *Acta Neuropathol* 129:729–748. <https://doi.org/10.1007/s00401-015-1406-3>
78. Wang Y, Mandelkow E (2016) Tau in physiology and pathology. *Nat Rev Neurosci* 17:22–35. <https://doi.org/10.1038/nrn.2015.1>
79. Wodzinski M, Marini N, Atzori M, Müller H (2024). DeeperHistReg: robust whole slide images registration framework. <https://doi.org/10.48550/arXiv.2404.14434>.
80. Wodzinski M, Marini N, Atzori M, Müller H (2024) Regwsi: whole slide image registration using combined deep feature- and intensity-based methods: winner of the ACROBAT 2023 challenge. *Comput Methods Programs Biomed* 250:108187. <https://doi.org/10.1016/j.cmpb.2024.108187>
81. Wodzinski M, Müller H (2021) Deephistreg: unsupervised deep learning registration framework for differently stained histology samples. *Comput Methods Programs Biomed* 198:105799. <https://doi.org/10.1016/j.cmpb.2020.105799>
82. Zupancic M, Mahajan MA, MD, Handa K, MD. Dementia with Lewy bodies: diagnosis and management for primary care providers. *PsychiatristCom* 2011. <https://www.psychiatrist.com/pcc/dementia-lewy-bodies-diagnosis-management-primary/> (accessed 29 May 2025).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.